Kamada (KMDA) Income from Continuing Operations (2012 - 2026)
Kamada (KMDA) posted quarterly Income from Continuing Operations of 6650000.0 for Q1 2026, down 28.2% year-on-year from 9262000.0 in Q1 2025, and up 12.6% on a QoQ basis from 5906000.0 in Q4 2025.
Kamada (KMDA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Income from Continuing Operations for 15 consecutive years, with 6650000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations fell 28.2% year-over-year to 6650000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20000328.0 (up 38.82% YoY) and the FY2025 annual result came in at 26736000.0, up 119.04% from the prior year.
- Income from Continuing Operations improved to 6650000.0 in Q1 2026 per KMDA's latest filing, from 5906000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for KMDA reached as high as 9262000.0 in Q1 2025 and fell as low as 1809.0 in Q1 2023.
- A 5-year average of 3292157.12 and a median of 3223000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The largest YoY upside for Income from Continuing Operations was 537066.67% in 2023 against a maximum downside of 100.1% in 2023.
- Year by year, Income from Continuing Operations stood at 3247000.0 in 2022, then surged by 53.68% to 4990000.0 in 2023, then slumped by 77.76% to 1110000.0 in 2024, then surged by 432.07% to 5906000.0 in 2025, then increased by 12.6% to 6650000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 6650000.0, 5906000.0, and 7438000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 6.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 6,328.00 |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4,552.00 |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | -1,809.00 |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 600.00 |
| Jun 30, 2022 | 3.95 Mn |
| Mar 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | -4.82 Mn |
| Sep 30, 2021 | 868,000.00 |
| Jun 30, 2021 | 965,000.00 |